DE602004024658D1 - Verfahren zur vermittlung von zellkulturreplikationsaktivität an unterschiedliche hepatitis-c-virus-isolate - Google Patents

Verfahren zur vermittlung von zellkulturreplikationsaktivität an unterschiedliche hepatitis-c-virus-isolate

Info

Publication number
DE602004024658D1
DE602004024658D1 DE602004024658T DE602004024658T DE602004024658D1 DE 602004024658 D1 DE602004024658 D1 DE 602004024658D1 DE 602004024658 T DE602004024658 T DE 602004024658T DE 602004024658 T DE602004024658 T DE 602004024658T DE 602004024658 D1 DE602004024658 D1 DE 602004024658D1
Authority
DE
Germany
Prior art keywords
replication activity
virus isolates
different
transferring cell
cell cultural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004024658T
Other languages
English (en)
Inventor
Jay Grobler
Osvaldo Flores
Eric J Markel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE602004024658D1 publication Critical patent/DE602004024658D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24251—Methods of production or purification of viral material
DE602004024658T 2003-02-13 2004-02-09 Verfahren zur vermittlung von zellkulturreplikationsaktivität an unterschiedliche hepatitis-c-virus-isolate Expired - Lifetime DE602004024658D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44731803P 2003-02-13 2003-02-13
PCT/US2004/003726 WO2004074507A2 (en) 2003-02-13 2004-02-09 Method to confer cell culture replication activity to different hepatitis c virus isolates

Publications (1)

Publication Number Publication Date
DE602004024658D1 true DE602004024658D1 (de) 2010-01-28

Family

ID=32908422

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004024658T Expired - Lifetime DE602004024658D1 (de) 2003-02-13 2004-02-09 Verfahren zur vermittlung von zellkulturreplikationsaktivität an unterschiedliche hepatitis-c-virus-isolate

Country Status (6)

Country Link
US (1) US7807455B2 (de)
EP (1) EP1604020B1 (de)
AT (1) ATE452192T1 (de)
CA (1) CA2514918C (de)
DE (1) DE602004024658D1 (de)
WO (1) WO2004074507A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1801116A1 (de) * 2005-12-21 2007-06-27 F. Hoffmann-La Roche Ag HCV-Replikon-Shuttlevektoren
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
EP2770055A1 (de) * 2008-12-26 2014-08-27 Toray Industries, Inc. Von Hepatitis-C-Virus abgeleitete Nukleinsäure sowie damit hergestellter Expressionsvektor, transformierte Zelle und Hepatitis-C-Virus-Teilchen
US20150072418A1 (en) * 2013-08-16 2015-03-12 Gilead Sciences, Inc. Hcv genotype 4d replicons

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1272179B (it) 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
US5744320A (en) 1995-06-07 1998-04-28 Promega Corporation Quenching reagents and assays for enzyme-mediated luminescence
DE19915178A1 (de) 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
IL152671A0 (en) 2000-05-23 2003-06-24 Univ Washington Hcv variants
AU2002225895A1 (en) * 2000-11-07 2002-05-21 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
DE60128835T2 (de) 2000-12-22 2008-03-20 Boehringer Ingelheim (Canada) Ltd., Laval Selbstreplizierendes rna-molekül aus hepatitis-c-virus
WO2002059321A2 (en) 2001-01-23 2002-08-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Hepatitis c virus replicons and replicon enhanced cells

Also Published As

Publication number Publication date
US7807455B2 (en) 2010-10-05
EP1604020B1 (de) 2009-12-16
CA2514918A1 (en) 2004-09-02
WO2004074507A3 (en) 2005-04-21
WO2004074507A8 (en) 2005-06-02
WO2004074507A2 (en) 2004-09-02
CA2514918C (en) 2012-07-03
EP1604020A4 (de) 2007-05-16
US20060228697A1 (en) 2006-10-12
EP1604020A2 (de) 2005-12-14
ATE452192T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
ATE499442T1 (de) Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz
ATE474847T1 (de) Verfahren zur herstellung von dipeptiden
ATE353911T1 (de) Verfahren zur rekombinanten herstellung von antifusogenikpeptide
ATE462000T1 (de) Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin
AR038595A1 (es) Cepas de metaneumovirus y su uso en formulaciones de vacunas y como vectores para la expresion de secuencias antigenicas
DE60326012D1 (de) Verfahren zur Konzentration von Proteinen
ATE244729T1 (de) Verfahren zur identifizierung von wirkstoffen gegen hcv durch verwendung von strukturkoordinaten der hepatitis-c-virus- protease
ATE456666T1 (de) Verfahren zur auswertung von ribonukleotidsequenzen
ATE334998T1 (de) Verfahren zur herstellung cyclischer peptide
DE602004024658D1 (de) Verfahren zur vermittlung von zellkulturreplikationsaktivität an unterschiedliche hepatitis-c-virus-isolate
DE602004022134D1 (de) Verfahren zur herstellung von dinitrilen
ATE542810T1 (de) Verfahren zur herstellung von 3,5-di-omikron-acyl-2-fluor-2-c-methyl-d-ribono gamma-lacton
DE502004005049D1 (de) Verfahren zur herstellung von amino-gruppen tragenden silicium-verbindungen
ATE427996T1 (de) Verfahren zur herstellung von (s)-butan-2-ol
ATE532863T1 (de) Verfahren zur anzucht von myokardzellen
ATE332905T1 (de) Verfahren zur herstellung von acylphosphinoxiden
DE60335766D1 (de) Verfahren zur Herstellung von m-Xylylendiamin
ATE405659T1 (de) Verfahren zur modulierung von cytokininabhängigen vorgängen in einer pflanze mittels b3-domäne- proteinen
ATE501272T1 (de) Verfahren zur produktion von pflanzen mit verbesserter transpirationseffizienz sowie davon produzierte pflanzen
DE60216416D1 (de) Verfahren zum nachweis von chloralhydrat in dichloressigsäure
DE502004002810D1 (de) Verfahren zur herstellung von copolymerisaten
ATE339523T1 (de) Verfahren zur herstellung von rekombinanten nukleinsäuremolekülen
ATE501282T1 (de) Verfahren zur herstellung von konzentraten
ATE410679T1 (de) Verfahren zur identifikation von antivirale substanzen
DE60229966D1 (de) Diabetesmodell

Legal Events

Date Code Title Description
8364 No opposition during term of opposition